1st Quarter - Report

ORGANOVO, INC. for ORGANOVO, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$70,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2017 $70,000 Replaced
1st Quarter - Amendment Apr 20, 2017 $60,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Issues related to the FY 17 and FY 18 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts.

LobbyistCovered position, as disclosed
PETER RUBIN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to the reauthorization of the Prescription Drug User Fee Act. Issues related to the implementation of PL 114-255, the 21st Century Cures Act.

LobbyistCovered position, as disclosed
PETER RUBIN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.